Haemonetics: 51% Surge in Share Price Amidst Recovery Hopes

Haemonetics has seen a 51% surge in its stock price over the past 30 days, despite a 12-month total shareholder return of -17.6%. The company's fair value is estimated at $83, higher than the recent closing price of $73.49, driven by rapid innovation, increased adoption of advanced plasma collection systems, and new software contracts securing market share. However, risks such as intensifying competition and dependence on a few core products could threaten growth if operational challenges persist.